Modality
ERT
MOA
CFTRmod
Target
FGFR
Pathway
Neuroinflam
ADHDLNEwing Sarcoma
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Jan 2030
Phase 1Current
NCT05086803
1,673 pts·LN
2020-04→2030-01·Not yet recruiting
1,673 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-01-043.8y awayPh2 Data· LN
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030
P1/2
Not yet…
Catalysts
Ph2 Data
2030-01-04 · 3.8y away
LN
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05086803 | Phase 1/2 | LN | Not yet recr... | 1673 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Darafutibatinib | BioNTech | Preclinical | PRMT5 | |
| ALN-8757 | Alnylam | Preclinical | TIGIT | |
| Ivotuximab | Madrigal Pharma | Phase 2 | CD123 | |
| Tixatapinarof | Recursion | Approved | FGFR |